TY  - JOUR
KW  - A53T
KW  -  Alpha-synuclein
KW  -  Parkinson disease
KW  -  Plasma
KW  -  Serum
TI  - Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease
SP  - 35
UR  - https://doi.org/10.1016/j.parkreldis.2020.03.014
EP  - 40
JF  - Parkinsonism & Related Disorders
AV  - public
ID  - discovery10099182
N1  - This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
A1  - Emmanouilidou, E
A1  - Papagiannakis, N
A1  - Kouloulia, S
A1  - Galaziou, A
A1  - Antonellou, R
A1  - Papadimitriou, D
A1  - Athanasiadou, A
A1  - Bozi, M
A1  - Koros, C
A1  - Maniati, M
A1  - Vekrellis, K
A1  - Ioannou, PC
A1  - Stefanis, L
VL  - 73
Y1  - 2020/04//
N2  - BACKGROUND: Variations of ?-synuclein levels have been reported in serum and plasma in Parkinson's Disease (PD) Patients. METHODS: Serum and plasma were obtained from PD patients without known mutations (GU-PD, n = 124)), carriers of the A53T/G209A point mutation in the ?-synuclein gene (SNCA) (n = 29), and respective age-/sex-matched controls. Levels of total ?-synuclein were assessed using an in-house ELISA assay. RESULTS: A statistically significant increase of ?-synuclein levels was found in serum, but not plasma, from GU-PD patients compared to healthy controls. A statistically significant decrease of ?-synuclein levels was found in serum and plasma from symptomatic A53T mutation carriers compared to healthy controls. Plasma ?-synuclein levels were modestly negatively correlated with UPDRS part III score and disease duration in A53T-PD patients. CONCLUSION: Increased ?-synuclein levels in serum of GU-PD patients suggest a systemic deregulation of ?-synuclein homeostasis in PD. The opposite results in A53T-PD highlight the complexity of ?-synuclein homeostatic regulation in PD, and suggest the possibility of reduced expression of the mutant allele.
ER  -